China's novel coronavirus pneumonia vaccine will enter clinical trials. On April 13, surging news notedChina's novel coronavirus (COVID-19) inactivated vaccine (Vero cell) phase I / II clinical trial developed by the national biological group Wuhan Biological Products Research Institute of China Limited is now under the "pre registration" pre registration status in the China clinical trial registration center.
China's second novel coronavirus vaccines registered for clinical trials have been registered in China after the Chen Wei team of academician of Chinese Academy of engineering and researcher of Military Medicine Academy of Military Academy.
With the severe situation of international epidemic situation, the development of new coronavirus vaccine is becoming more and more urgent. According to the press conference of the joint prevention and control mechanism of the State Council, China has chosen five technical routes to accelerate the research and development of new coronavirus vaccine after the outbreak, namely inactivated vaccine, gene engineering recombinant subunit vaccine, adenovirus vector vaccine, attenuated influenza virus vector vaccine and nucleic acid vaccine. It can be seen that the five technical routes adopted by China cover the main types of new coronavirus vaccines under development all over the world.
The novel coronavirus novel coronavirus (COVID-19) inactivated vaccine (Vero cell) is randomized, double-blind, placebo controlled parallel phase I / II clinical trial, and the scientific name of the research is: evaluation of the new coronavirus inactivated vaccine (Vero cell) at 6 years old and above, the registration of clinical trial registration information shows that the Wuhan Biological Products Research Institute Co., Ltd. A randomized, double-blind, placebo-controlled phase I / II clinical trial on the safety and immunogenicity of vaccination in the population.
at present, the clinical study has been approved by the ethics committee and is in a "pass audit" pre-registration state.
"China biology has made important achievements in the research and development of new cap inactivated vaccine, which is expected to provide a" trump card "for the decisive victory in the fight against the epidemic." Liu Jingzhen, chairman of Sinopharm, said at a press conference on the afternoon of April 8 held by the joint defense and control mechanism of the State Council.
According to surging news on April 12, academician Zhong Nanshan once said at a connecting meeting with Korean epidemic prevention experts that at present, the five vaccines in China have been developed simultaneously, and at present, adenovirus vector vaccine and all inactivated vaccine are developing rapidly. The first phase of clinical trial of adenovirus vaccine has been started, and the clinical trial of all inactivated vaccine will be started soon. "We need to observe it for a period of time after the clinical trial, usually one to two years, but it is also possible that it may be listed in advance due to the development of the disease."
China's biological novel coronavirus pneumonia was the novel coronavirus pneumonia vaccine. Yang Xiaoming, the Chinese biological director, introduced the five technologies of the new crown pneumonia vaccine in China, which was developed rapidly and technically mature. "I believe the new crown vaccine will soon meet with you," said Chinese biotic chairman, 11, the day before the day.
According to the previous statistics of the World Health Organization (who), as of March 21, there are 51 candidate vaccines in the world, two of which have entered the clinical trial stage. One is that Moderna, an American biotechnology company, announced on March 16 local time that the mRNA vaccine developed by the company has started human trials.
Another is the research team led by chen wei, an academician of the chinese academy of engineering and a researcher at the institute of military medicine of the academy of military sciences. The recombinant new coronavirus (2019- COV) vaccine was approved for clinical trial at 20.18 hours on march 16. So far, Chen Wei team is recruiting phase II clinical trial volunteers for clinical trials.
Novel coronavirus (COVID-19) inactivated vaccine developed by the national biological group Wuhan Institute of biological products, China Limited, will be the third new crown vaccine in the world.
How long will it take to develop a new vaccine that can be used on a large scale? The World Health Organization's director-general, Tham Desai, said at a regular press conference that the new crown vaccine will take at least 12 to 18 months to develop. Anthony Fucci, director of the National Institute of Allergy and Infectious Diseases, said earlier that even if the initial safety tests of the vaccine went well, it would take a year to a half before it could be used on a large scale.